Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma

The purpose of the study is to evaluate the effect of Elranatamab therapy after cilta-cel measuring how long a patient with high risk relapsed myeloma lives without the myeloma getting worse(progressing), also known as progression-free survival (PFS). Patients with clinical high-risk myeloma, defined as having history of myeloma that has grown outside of the bones or having high risk mutations in the myeloma cells, benefit less from cilta-cel compared to myeloma patients without these characteristics.

NCT Number	NCT06947083
Lead Sponsor	H. Lee Moffitt Cancer Center and Research Institute Collaborators: Pfizer
Conditions	Myeloma
Enrollment	39 participants
Start Date	2025-05-27
Primary Completion	2029-04 (estimated)
Study Completion	2029-04 (estimated)
Updated on ClinicalTrials.gov	2025-12-03